ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,300.33
-0.14%
Dow Jones
43,828.06
-0.20%
Gold vs US Dollar
2,648.955
0.00%
Brent Oil
74.135
0.00%
Bitcoin
102,330.01
0.92%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Basilea Pharmaceutica Ag (0QNA)

  7. Basilea Pharmaceutica Ag (0QNA) News

Basilea Pharmaceutica (0QNA)

Basilea Pharmaceutica Ag
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0QNA
DateTimeSourceHeadlineSymbolCompany
10/10/202405:15UK RegulatoryStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this yearLSE:0QNABasilea Pharmaceutica Ag
10/10/202405:15UK RegulatoryStarke Cresemba® (Isavuconazol)-Umsätze in Asien-Pazifik und China lösen vierte Meilensteinzahlung für diese Region in diesem Jahr an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
24/09/202405:15UK RegulatoryBasilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasisLSE:0QNABasilea Pharmaceutica Ag
24/09/202405:15UK RegulatoryBasilea initiiert klinische Phase-3-Studie mit Antipilzmittel Fosmanogepix bei Candidämie und invasiver CandidiasisLSE:0QNABasilea Pharmaceutica Ag
19/09/202405:15UK RegulatoryBasilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial fundingLSE:0QNABasilea Pharmaceutica Ag
19/09/202405:15UK RegulatoryBasilea schliesst Vereinbarung mit BARDA zur Entwicklung neuartiger Medikamente für die Behandlung von Infektionen durch Pilze und Bakterien ab und erhält erste FörderungLSE:0QNABasilea Pharmaceutica Ag
06/09/202405:15UK RegulatoryStrong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
06/09/202405:15UK RegulatoryStarke Cresemba® (Isavuconazol)-Verkäufe in Europa lösen USD 25 Mio. Umsatzmeilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
27/08/202405:15UK RegulatoryEntscheidung der Europäischen Kommission zur Zulassung von Antipilzmittel Cresemba® (Isavuconazol) bei Kindern und Verlängerung der Marktexklusivität löst CHF 10 Mio. Meilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
27/08/202405:15UK RegulatoryEuropean Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
21/08/202405:15UK RegulatoryStarke Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
21/08/202405:15UK RegulatoryStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
13/08/202405:15UK RegulatoryBasilea meldet starke Halbjahresergebnisse 2024 und erhöht signifikant den Ausblick für Umsatz und Gewinn für das GesamtjahrLSE:0QNABasilea Pharmaceutica Ag
13/08/202405:15UK RegulatoryBasilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidanceLSE:0QNABasilea Pharmaceutica Ag
20/06/202405:15UK RegulatoryBasilea verpartnert Onkologie-Wirkstoffkandidat Lisavanbulin mit Glioblastoma FoundationLSE:0QNABasilea Pharmaceutica Ag
20/06/202405:15UK RegulatoryBasilea partners oncology drug candidate lisavanbulin with Glioblastoma FoundationLSE:0QNABasilea Pharmaceutica Ag
16/05/202405:15UK RegulatoryStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
16/05/202405:15UK RegulatoryStarke Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
03/05/202405:15UK RegulatoryBasilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024LSE:0QNABasilea Pharmaceutica Ag
03/05/202405:15UK RegulatoryBasilea berichtet über Präsentation neuer Daten zu Ceftobiprol (Zevtera®) auf dem Fachkongress ESCMID Global 2024LSE:0QNABasilea Pharmaceutica Ag
24/04/202416:00UK RegulatoryBasilea-Aktionäre genehmigen an der Generalversammlung alle Anträge des VerwaltungsratsLSE:0QNABasilea Pharmaceutica Ag
24/04/202416:00UK RegulatoryBasilea shareholders approve all proposals of the board of directors at the annual general meetingLSE:0QNABasilea Pharmaceutica Ag
09/04/202405:15UK RegulatoryBasilea awarded CARB-X grant to develop recently acquired novel class of antibioticsLSE:0QNABasilea Pharmaceutica Ag
09/04/202405:15UK RegulatoryBasilea erhält CARB-X-Förderung für die Entwicklung einer kürzlich erworbenen neuen Antibiotika-WirkstoffklasseLSE:0QNABasilea Pharmaceutica Ag
04/04/202405:15UK RegulatoryBasilea gibt Erhalt der US-FDA-Zulassung für Antibiotikum ZEVTERA® (Ceftobiprol-Medocaril) für drei Indikationen bekanntLSE:0QNABasilea Pharmaceutica Ag
04/04/202405:15UK RegulatoryBasilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicationsLSE:0QNABasilea Pharmaceutica Ag
11/03/202406:15UK RegulatoryContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
11/03/202406:15UK RegulatoryAnhaltend gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
13/02/202406:15UK RegulatoryBasilea meldet starkes Gesamtjahr 2023 mit einer über der Guidance liegenden Profitabilität trotz substanziell erweitertem F&E-PortfolioLSE:0QNABasilea Pharmaceutica Ag
13/02/202406:15UK RegulatoryBasilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolioLSE:0QNABasilea Pharmaceutica Ag
 Showing the most relevant articles for your search:LSE:0QNA

Your Recent History

LSE
BOO
Boohoo
LSE
POS
Plexus
LSE
ZED
Zenova
LSE
GKP
Gulf Keystone Petroleum
LSE
BARC
Barclays
LSE
TW.
Taylor Wimpey
LSE
VRS
Versarien
LSE
AGL
Angle
LSE
APTA
Aptamer
LSE
GSF
Gore Street Energy Storage
LSE
SBTX
Skinbiotherapeutics
LSE
GENF
Genflow Biosciences
LSE
LIT
Litigation Capital Manag...
LSE
LLOY
Lloyds Banking
LSE
SCLP
Scancell
LSE
ULT
Ultrasis
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved